Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

Our data indicate that blocking the complement system exacerbates LCWE-induced KD vasculitis, potentially by impairing C3-mediated clearance of bacterial components. Our studies reveal the ...

This systematic review comprehensively summarizes treatment approaches for all types of age-related macular degeneration (AMD ...

EU Unveils Voluntary AI Code to Complement Groundbreaking AI Act The European Union has introduced a voluntary code of practice for general-purpose AI, complementing its existing AI Act. This code ...

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

"Eleva commences Phase I clinical trial for C3G treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The fourth fundamental circuit component that is frequently employed to design nanoscale electronic devices is memristor. The compact size, non-volatility, and low power of memristor, combined with ...

Therefore, it’s premature to assume that C3.ai can replicate NVIDIA’s success. NVIDIA stock is expected to outperform C3.ai’s due to its stronger profitability and market position.